Literature DB >> 27999756

Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.

Sina Fellermeier1, Nadine Beha1, Jan-Erik Meyer1, Sarah Ring1, Stefan Bader1, Roland E Kontermann1, Dafne Müller1.   

Abstract

Co-stimulation via receptors of the tumor necrosis factor superfamily (TNFSF) emerges as promising strategy to support antitumor immune responses. Targeted strategies with antibody-fusion proteins composed of a tumor-directed antibody part and the extracellular domain of a co-stimulatory ligand of the TNFSF constitute an attractive option to focus the co-stimulatory activity to the tumor site. Since TNFSF members intrinsically form functional units of non-covalently linked homotrimers, the protein engineering of suitable antibody-fusion proteins is challenging. Aiming for molecules of simple and stable configuration, we used TNFSF ligands in a single-chain format (scTNFSF), i.e., three units of the ectodomain connected by polypeptide linkers, folding into an intramolecular trimer. By fusing tumor-directed scFv antibody fragments directed against EpCAM or FAP to co-stimulatory scTNFSF molecules (sc4-1BBL, scOX40L, scGITRL or scLIGHT), a set of monomeric scFv-scTNFSF fusion proteins was generated. In comparison to the scFv-TNFSF format, defined by intermolecular homotrimerization via the TNFSF part, scFv-scTNFSF showed equal or enhanced co-stimulatory activity despite reduced avidity in antibody binding. In addition, enhanced serum stability and improved bioavailability in mice were observed. We show that the scFv-scTNFSF format can be applied to various members of the TNFSF, presenting targeting-dependent co-stimulatory activity. Hence, this format exhibits favorable properties that make it a promising choice for further therapeutic fusion protein development.

Entities:  

Keywords:  Antibody-fusion proteins; TNFSF ligands; cancer immunotherapy; co-stimulation

Year:  2016        PMID: 27999756      PMCID: PMC5139625          DOI: 10.1080/2162402X.2016.1238540

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  37 in total

Review 1.  Antibody fusions with immunomodulatory proteins for cancer therapy.

Authors:  Dafne Müller
Journal:  Pharmacol Ther       Date:  2015-07-03       Impact factor: 12.310

2.  Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.

Authors:  B Brocks; P Garin-Chesa; E Behrle; J E Park; W J Rettig; K Pfizenmaier; D Moosmayer
Journal:  Mol Med       Date:  2001-07       Impact factor: 6.354

3.  Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily.

Authors:  Teresa Hemmerle; Christian Hess; Dario Venetz; Dario Neri
Journal:  J Biotechnol       Date:  2013-12-30       Impact factor: 3.307

Review 4.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

5.  Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.

Authors:  Agnes Wyzgol; Nicole Müller; Andrea Fick; Sabine Munkel; Goetz Ulrich Grigoleit; Klaus Pfizenmaier; Harald Wajant
Journal:  J Immunol       Date:  2009-07-13       Impact factor: 5.422

Review 6.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

7.  Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.

Authors:  Nora Hornig; Katharina Reinhardt; Vanessa Kermer; Roland E Kontermann; Dafne Müller
Journal:  Cancer Immunol Immunother       Date:  2013-05-30       Impact factor: 6.968

Review 8.  Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.

Authors:  Miguel F Sanmamed; Fernando Pastor; Alfonso Rodriguez; Jose Luis Perez-Gracia; Maria E Rodriguez-Ruiz; Maria Jure-Kunkel; Ignacio Melero
Journal:  Semin Oncol       Date:  2015-06-11       Impact factor: 4.929

9.  An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

Authors:  Martin Siegemund; Oliver Seifert; Maria Zarani; Tamara Džinić; Valentino De Leo; Doris Göttsch; Sabine Münkel; Meike Hutt; Klaus Pfizenmaier; Roland E Kontermann
Journal:  MAbs       Date:  2016-04-11       Impact factor: 5.857

10.  Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function.

Authors:  Kausik Chattopadhyay; Udupi A Ramagopal; Arunika Mukhopadhaya; Vladimir N Malashkevich; Teresa P Dilorenzo; Michael Brenowitz; Stanley G Nathenson; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

View more
  18 in total

Review 1.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

2.  Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Authors:  Christina Claus; Claudia Ferrara; Wei Xu; Johannes Sam; Sabine Lang; Franziska Uhlenbrock; Rosmarie Albrecht; Sylvia Herter; Ramona Schlenker; Tamara Hüsser; Sarah Diggelmann; John Challier; Ekkehard Mössner; Ralf J Hosse; Thomas Hofer; Peter Brünker; Catherine Joseph; Jörg Benz; Philippe Ringler; Henning Stahlberg; Matthias Lauer; Mario Perro; Stanford Chen; Christine Küttel; Preethi L Bhavani Mohan; Valeria Nicolini; Martina Carola Birk; Amandine Ongaro; Christophe Prince; Reto Gianotti; Gregory Dugan; Christopher T Whitlow; Kiran Kumar Solingapuram Sai; David L Caudell; Armando G Burgos-Rodriguez; J Mark Cline; Michael Hettich; Maurizio Ceppi; Anna Maria Giusti; Flavio Crameri; Wouter Driessen; Peter N Morcos; Anne Freimoser-Grundschober; Victor Levitsky; Maria Amann; Sandra Grau-Richards; Thomas von Hirschheydt; Stella Tournaviti; Michael Mølhøj; Tanja Fauti; Viola Heinzelmann-Schwarz; Volker Teichgräber; Sara Colombetti; Marina Bacac; Alfred Zippelius; Christian Klein; Pablo Umaña
Journal:  Sci Transl Med       Date:  2019-06-12       Impact factor: 17.956

Review 3.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

4.  An engineered 4-1BBL fusion protein with "activity on demand".

Authors:  Jacqueline Mock; Marco Stringhini; Alessandra Villa; Michael Weller; Tobias Weiss; Dario Neri
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-25       Impact factor: 11.205

Review 5.  Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.

Authors:  Patrizia Murer; Dario Neri
Journal:  N Biotechnol       Date:  2019-04-13       Impact factor: 5.079

6.  A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies.

Authors:  Roberto De Luca; Paul Kachel; Klara Kropivsek; Berend Snijder; Markus G Manz; Dario Neri
Journal:  Protein Eng Des Sel       Date:  2018-05-01       Impact factor: 1.650

7.  Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.

Authors:  Roberto De Luca; Dario Neri
Journal:  Cancer Immunol Immunother       Date:  2018-07-04       Impact factor: 6.968

8.  A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.

Authors:  Nadine Aschmoneit; Sophia Steinlein; Lennart Kühl; Oliver Seifert; Roland E Kontermann
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

9.  Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.

Authors:  Meike Hutt; Sina Fellermeier-Kopf; Oliver Seifert; Lisa C Schmitt; Klaus Pfizenmaier; Roland E Kontermann
Journal:  Oncotarget       Date:  2018-01-31

10.  Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans.

Authors:  Sina Fellermeier-Kopf; Friederike Gieseke; Ugur Sahin; Dafne Müller; Klaus Pfizenmaier; Roland E Kontermann
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.